MIRM’s FOP approval is real; the first-year revenue bridge is not

Summary: The FDA approved Mirum’s once-daily Atebrioz for FOP patients aged 12 and older, with U.S. availability expected in October. But the greater-than-$200 million figure management cited is a global peak-sales estimate for the full brand, not launch-year guidance. Mirum’s latest $680–$700 million sales guide does not quantify Atebrioz uptake, while the license requires an approval milestone and royalties to Incyte. A price-only, 12-month sensitivity has a near-flat base and 24% downside. Reject / no trade.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Mirum Pharmaceuticals (MIRM)	Long	FDA-approved FOP launch option versus a high existing-sales multiple and no disclosed launch-price, payer, or uptake bridge	FDA and Incyte approval releases Sep. 25; latest close Sep. 25; Q2 filing Aug. 5	U.S. launch expected October 2026; initial uptake and pricing disclosure	Approval was followed by a reported $90.06 after-hours mark, only +0.4% versus close; exact trading composition is unknown	Reject: base +0.3%, bottom stress -24.1%, weighted value -1.9%	Nasdaq common; no post-approval regular-session acceptance or execution-quality audit	First-year product economics, patient access and dilution are not yet quantified
2	Marygold Companies (MGLD)	Long	$2.00 cash take-private offer versus $1.93 Sep. 25 close	Definitive agreement announced Sep. 25	Expected H1 2027 close, subject to approvals	75% support agreements reported; current arbitrage ownership unknown	Reject: 3.6% gross upside versus about -48% to the unaffected $1.00 price on a break	NYSE American micro-cap; exit quality unverified	Capped offer spread and standalone reversal dominate the upside
3	Aurora Innovation (AUR)	Long	2030 driverless scale targets versus current commercial revenue, fleet production and cash consumption	Investor Day filing Sep. 23; Q2 10-Q July 29	200-driverless-truck exit target for 2026; 1H 2027 gross-margin break-even target	Customer allocation and supplier ramp are company-reported; independent demand/flow evidence absent	Reject: long-dated target is not a supportable near-term 10/5 base case	Nasdaq common; liquid relative to the micro-cap, but current execution still unverified	The 30,000-truck/$5B 2030 vision is a forecast dependent on production, customer contracts and financing

Selected opportunity: MIRM, for the freshest verified operating catalyst and the clearest existing commercial base. This is a research ranking, not a claim that it is a qualifying long.

Why this one now: FDA approval is a completed state change, unlike a pending PDUFA. The next question is economic: whether an October launch can add enough net sales, quickly enough, to justify a price already equal to about 8.4 times Mirum’s 2026 sales midpoint.

What should surprise the reader: The approval is not the same as a revenue forecast. The only greater-than-$200 million estimate found in the reviewed run was management’s global peak-sales estimate for the full product, as transcribed from the May Q1 call. It is not a first-year guide, and Mirum has not disclosed an Atebrioz price or launch contribution.

Why This Is the Best Opportunity Right Now

MIRM has a growing commercial platform, a definitive FDA approval and a planned U.S. launch within weeks. Its Q2 2026 net product sales were $176.2 million, up from $127.8 million a year earlier, and management raised full-year net product sales guidance to $680–$700 million. That gives the new product an existing commercial and patient-support infrastructure rather than a pre-revenue company’s launch burden.

The June 23 Yext screen mentioned MIRM only as a convertible-refinancing comparison before this approval. This screen covers a materially new issuer-specific boundary: an approved FOP product and its launch economics.

The price has not yet had a regular-session chance to accept the approval. MIRM closed at $89.70 on Sep. 25 before the 7:00 p.m. EDT approval release. One quote page shows $90.06 after hours at 7:56 p.m., only 0.4% above the close. That is context, not proof the market has settled on the news. The market was closed for the weekend, and no post-approval regular-session quote exists in this run.

MGLD’s contractual $2 offer caps upside below 4%, while AUR’s current commercial revenue remains far below the scale in its 2030 vision. MIRM ranks first by the combination of current commercial operations and a now-approved product, but the crucial incremental sales and net-price inputs remain unknown.

Why This Can Move More Than 5% Soon

The October launch, label details, payer access and first prescriptions can move the estimate of Atebrioz’s near-term contribution by more than 5%. The FDA approved the drug to reduce total new heterotopic-ossification volume. The pivotal basis was a 63-patient randomized, double-blind, placebo-controlled 24-week period, where mean lesion volume fell 3.2 cm³ on treatment and rose 24.6 cm³ on placebo. The approval is firm; the pace of adoption and the commercial economics are not.

The cheapest falsification is Mirum’s first post-launch update: reported net sales, number of patients on therapy, payer access and net price. The company and Incyte say Atebrioz should be available in October through Mirum Access Plus, with eligible patients paying as little as $0 monthly. That is a copay-support statement, not the drug’s gross list price, realized net price or covered lives.

10/5 Asymmetry Gate

Reject / no trade. The reference is $89.70 at the Sep. 25, 2026 regular close, before the approval release. The highest-probability 12-month base sensitivity is $89.94 (+0.3%); the bottom is $68.07 (-24.1%). Base reward to adverse risk is about 0.01:1. The 18%/57%/25% price-weighted value is $87.99 (-1.9%) before costs. These are reference-only model outputs, not price bounds. The model fails the long hurdle on base return, adverse risk and weighted value.

What Should Surprise the Reader

Mirum does not own every dollar associated with approval. Its SEC-filed Incyte license requires a $25 million U.S. approval milestone, up to $48 million total regulatory milestones, up to $15 million commercial milestones and mid-to-high single-digit royalties on worldwide net sales. The rare-pediatric-disease priority review voucher from this approval belongs to Incyte, not Mirum. The $25 million approval milestone is a real economic cost even though it is modest relative to Mirum’s market value.

FOP is ultra-rare: the joint issuer release estimates about 300 people in the United States and 900 worldwide. Management said on the Q1 call that its global peak-sales estimate was “$200 million plus” for the full brand across its target markets. That estimate helps frame scale, but it is not a sales forecast for the first year or proof of price and reimbursement. A fast market sometimes treats approval, launch and peak sales as if they were one event; they are three separate gates.

The Setup

Mirum commercializes LIVMARLI and bile-acid medicines and is developing additional rare-disease therapies. Q2 net product sales rose to $176.2 million; the 2026 guide midpoint is $690 million. In the six months ended June 30, 2026, operating cash flow was negative $273.0 million, heavily affected by the Bluejay asset acquisition, non-cash acquired IPR&D, note-exchange expense and working-capital changes. It should not be annualized as a normal burn rate. Management says June unrestricted cash, cash equivalents and investments of $561.3 million fund at least 12 months from the filing; the $690 million 0% notes due 2032 and $79.0 million 4% notes due 2029 remain claims.

The share denominator also matters. The SEC cover reports 64.932 million common shares outstanding as of July 31. At $89.70, that implies about $5.82 billion equity value. The Q2 filing also lists outstanding equity awards, shares issuable on convertible-note settlement and pre-funded warrants. These are not all shares already issued or freely tradable, but they are possible claims on future per-share value. The model uses only the dated July 31 outstanding share count and does not add these potential claims.

The Market Price

The scenario reference is $89.70 at the Sep. 25, 2026 regular close (4:00 p.m. EDT). MarketBeat reports a $90.81 high, $88.28 low, 762,587 shares and a $5.82 billion market cap. A ChartExchange historical page showed $89.66, a four-cent close discrepancy; the model uses MarketBeat’s $89.70 quote, also shown by StockAnalysis. The SEC-filed 64.932 million shares as of July 31 multiplied by $89.70 implies about $5.82 billion. A separate finance feed’s market-cap field was lower at $5.68 billion despite showing the same $89.70 quote; that conflict is not used to construct the scenarios.

Incyte/Mirum released the approval announcement at 7:00 p.m. EDT, after the close. StockAnalysis displayed an after-hours mark of $90.06 at 7:56 p.m. EDT, +0.4% from the close. This is reference context only. No post-approval regular session had occurred by this research run, so price acceptance, spread, depth, venue, volume quality and exit liquidity are unverified.

The Mispricing

The bull interpretation is that an approved, once-daily oral therapy opens a second rare-genetic-disease franchise inside a company already growing product revenue. On the other side, Mirum’s price already capitalizes a large commercial business and several pipeline options. Using $5.824 billion equity value divided by $690 million midpoint sales guidance gives a price-to-sales reference of about 8.44×. This is an equity-sales measure; the company has approximately $208 million net debt on June 30 figures before the newly triggered $25 million Incyte milestone, and this net-debt claim is not folded into the price-only scenario map.

The market may be underestimating uptake, given the 300-person U.S. population and specialized treatment centers. It may also be right to discount timing: launch is still ahead, the available trial had 63 patients with a 24-week randomized period, price has not been disclosed, and there are other approved FOP therapies. Commercial proof, not the approval announcement alone, closes the remaining gap.

The Positioning

The approval was announced after the regular session. The regular close and $90.06 after-hours mark establish a modest first indication, not durable price acceptance. Friday’s volume was about 763,000 shares, but the available sources do not establish who bought, whether holders were forced to cover, or how much event positioning sits in options.

Current beneficial ownership, short interest, borrow, option open interest, dealer exposure and same-session flows were not verified. Volume and a 0.4% after-hours move are observations, not evidence of a crowded trade or a market-implied approval probability.

The Catalyst

Step	Timing and status	Observable test	Failure mode
FDA approval	Completed; announced after the Sep. 25 regular close	Confirm final label, age range, endpoint, warnings and approved dose in FDA documents	Label/access narrower than the commercial thesis assumes
U.S. commercial availability	Company expects October 2026	Verify launch date, WAC/list price, payer coverage, first prescriptions and net-price/discount structure	Slow prior authorizations, patient identification or access despite copay support
First sales disclosure	Next quarterly reporting and management updates	Compare reported Atebrioz revenue and patients treated with any disclosed outlook	Revenue remains small versus the growth already embedded in MIRM valuation
Incyte payment obligations	$25M U.S. approval milestone triggered; additional milestones and royalties remain conditional	Reconcile payment, royalty accounting and any later milestones in quarterly filings	Higher costs or lower net revenue reduce commercial contribution

The Payoff

Because the quote and balance sheet are not contemporaneous with the approval, this is a price-only price-to-sales sensitivity, not an enterprise-value appraisal or an executable model. Reference equity capitalization uses $89.70 and the last SEC-reported share count of 64.932 million as of July 31, producing about $5.824 billion, or 8.44× Mirum’s $690 million 2026 sales-guide midpoint. The SEC filing reported June 30 net debt of about $207.7 million and the new approval triggers a $25 million milestone; those claims are discussed separately, not mixed into the scenario formula. Potential conversion and equity-award dilution is also excluded.

For the 12 months to Sep. 25, 2027, I assume current-product sales near the $690 million guide midpoint and add Atebrioz sales of $100 million in the top case, $40 million in the base and zero in the bottom. Those are analyst assumptions—not Mirum guidance. They represent 50%, 20% and 0% of management’s greater-than-$200 million global peak-sales estimate for the full brand; that estimate is not a launch-year forecast. Exit price-to-sales assumptions are 9.0×/8.0×/6.5×. Probabilities of 18%/57%/25% reflect a limited first-year adoption window, unknown price/access and the possibility that the existing portfolio both grows and diversifies the commercial outcome.

The price formula is target = $89.70 × (scenario sales / $690M) × (scenario price-to-sales multiple / 8.44×). It holds the share denominator and baseline market capitalization constant and excludes the separately discussed debt/cash claims because the latest balance-sheet date is June 30 and the quote is Sep. 25. It is a reference-only equity-price sensitivity, not an enterprise-value estimate or a forecast.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	18%	$109.50	+22.1%	12 months to Sep. 25, 2027	$790M assumed sales ($690M existing base + $100M Atebrioz), 9.0× price/sales	Low; launch and multiple assumptions
Base Case	57%	$89.94	+0.3%	12 months to Sep. 25, 2027	$730M assumed sales ($690M base + $40M Atebrioz), 8.0× price/sales	Medium for existing guide, low for launch sales/multiple
Bottom Case	25%	$68.07	-24.1%	12 months to Sep. 25, 2027	$680M guide low, no material launch contribution, 6.5× price/sales	Low; downside stress, not a floor
Invalidation	n/a	New sales fail to offset launch costs, royalty, $25M milestone and continuing pipeline spend	Rebuild at then-current quote and disclosed sales, debt, cash and shares	Next filings	Verify product sales, share count, convertible settlement, milestone/royalty payments and operating cash flow	Medium

Probability-weighted expected value: $87.99, or -1.9% before costs (0.18×$109.50 + 0.57×$89.94 + 0.25×$68.07). Current market level and timestamp: $89.70, Sep. 25, 2026, 4:00 p.m. EDT regular close; $90.06 was an after-hours reference at 7:56 p.m. EDT. Primary instrument: None; comparison is unlevered Nasdaq common stock only. 10/5 favorable base move: +0.3%. 10/5 credible adverse move: -24.1% modeled stress; downside is not capped. 10/5 measurement basis: reference-only. 10/5 status: Reject. Confidence: Low; price, payer access, launch uptake, convertible value and future shares are not fully reconciled.

At the current 8.44× price-to-sales reference, a +10% price requires about $759 million in sales—$69 million above the $690 million guide midpoint—if the multiple holds. If the exit multiple is 8.0×, sales would need to be about $801 million to support +10%. The $69 million increment is roughly 35% of management’s greater-than-$200 million global peak estimate; that is a scale comparison, not a claim that 35% of peak sales is achievable in the first year. The approved label, 300 U.S./900 global estimated patients, price, reimbursement and uptake make the bridge uncertain. The approval is valuable; it does not by itself validate either break-even threshold.

The Kill Shot

The strongest bull case is not speculative biology: FDA has granted approval after a randomized, placebo-controlled study, and the oral option fits a concentrated rare-disease ecosystem. Mirum says it expects October availability and already reported growing sales in its existing portfolio. It also has an estimated $200 million-plus global peak opportunity for the full FOP brand according to management’s Q1 call.

The most fragile assumption in the long is that a small pool of diagnosed patients converts quickly into meaningful net sales at a price and reimbursement level that produces substantial profit after the Incyte royalty and launch expense. Approval reduces regulatory risk but does not establish actual patients on therapy, net price, persistence, payor coverage, or the path to the peak estimate. At 8.4× current sales, existing operations already carry a premium; a flat base and deeper downside remain credible even if Atebrioz succeeds clinically.

What Could Go Wrong

Launch uptake is limited by the ultra-rare population, diagnostic/access barriers, payer prior authorization, competing therapies, tolerability or patient choice.
The approved 24-week lesion-volume endpoint and longer open-label extension do not translate into broad adoption or durable improvements beyond the label’s measured outcome.
Net realized price, discounts and copay support differ from gross pricing expectations; the company has not yet disclosed a list price or sales guide for Atebrioz.
Incyte receives a $25 million approval milestone, additional milestones and mid-to-high single-digit royalties; it also owns the rare-pediatric-disease priority review voucher.
Existing products miss the $680–$700 million 2026 sales guide, or broader pipeline/launch costs keep operating cash flow below management’s 2027 positive-cash-flow goal.
The June 30 balance sheet and July 31 share count are stale relative to the Sep. 25 close. $79 million 2029 and $690 million 2032 notes, note conversion terms, equity awards and potential share issuance affect the equity claim.
No post-approval regular session, current spread/depth, venue quality, volume quality or exit liquidity was available on this weekend research run. Gaps and slippage can exceed model sensitivities.

What Would Prove This Wrong

The rejection would be too conservative if Mirum discloses a net price and payer coverage that support rapid uptake, posts patient and sales evidence consistent with at least $759 million in the modeled 12-month total sales case, and converts the approved product into durable cash contribution while meeting the existing portfolio guide. A fresh regular-session quote would still be required, and the scenario would need a credible bottom within -5%, not merely a favorable launch update.

Risk Audit

The bottom case is a sales/multiple compression stress, not a worst case. A weak label interpretation, payer delay, patient-recruitment/diagnosis bottleneck, competing treatment, safety event, R&D overrun, note conversion, dilution or disappointing existing portfolio could produce a larger loss. The $25 million milestone is not the main risk; the larger issue is whether the incremental contribution warrants the valuation and converts to cash. No 5% stop is assumed to cap a gap. No live execution conditions were verified.

Best Trade Strategy

No trade. Keep entry.price=null and execution.can_execute=false. Use the Sep. 25 regular close at $89.70 as the research reference; treat $90.06 after hours as context only, not a regular-session acceptance price. Reassess after the first regular session following the approval and after pricing/coverage plus the first sales update. Verify a fresh quote, spread, depth, venue quality, volume quality and exit capacity before considering ordinary common shares. No options, leverage, margin, market orders or price-floor logic.

Sources

FDA approval notice for Atebrioz, Sep. 25/26; labeled age range, 63-patient randomized period, endpoint and trial results.
Mirum and Incyte approval release, Sep. 25 at 7:00 p.m. EDT; October availability, program support, global 300/900 patient estimates, Incyte ownership/licensing and PRV.
Mirum Q2 2026 Form 10-Q, filed Aug. 5; cash/investments, $769M note principal, Q2 capitalization, shares as of July 31, potential conversion/equity claims, operating cash flow and Incyte license terms.
Mirum Q2 2026 results and business update, Aug. 5; net product sales, 2026 guide, pipeline and license context.
Mirum Q1 2026 earnings-call transcript, third-party transcript of management’s call; management described global peak sales above $200M for the full brand, not launch-year guidance.
MIRM Sep. 25 historical quote, secondary price source; $89.70 regular close, day range and volume.
MIRM Sep. 25 after-hours quote, secondary source; $90.06 at 7:56 p.m. EDT. This follows the company’s 7:00 p.m. approval release and is context only.
Marygold $2 take-private release, Sep. 25 Business Wire release republished by StockTitan; offer, support agreements and closing conditions.
MGLD Sep. 25 close and volume, secondary price data; $1.93 and 15.50M shares, comparison only.
Aurora Sep. 23 Investor Day filing, issuer slides; 200/1,000/30,000 truck targets, $5B revenue goal, $80M 2026 exit run-rate and 2027 break-even target.
Aurora Q2 2026 Form 10-Q, issuer filing; H1 revenue, operating loss, liquidity and financing context, comparison only.

Research Quality Scorecard

Criterion	Score	Evidence and deduction
Market disagreement	4/5	A confirmed approval adds a product option, but current valuation and the launch-dollar bridge remain unresolved
Evidence base	5/5	Fresh FDA/partner approval release, SEC filing, commercial guide and reference price; no launch economics yet
Positioning and flows	2/5	Close and one AH mark are observed; current ownership, short/option position and Monday acceptance are unknown
Catalyst path	4/5	October availability and first net-sales report are observable; payor coverage and adoption are conditional
Payoff architecture	2/5	Explicit price/sales sensitivities fail base upside, risk and weighted-value hurdles
Invalidation discipline	4/5	Net sales, payer access, milestone payment, notes and dilution claims can be checked in filings
Differentiated insight	4/5	Separates approval, access, patient starts, net sales, global peak estimate and Incyte’s economic rights
Client value	4/5	Shows why an FDA approval and $200M peak claim do not equal an investable first-year per-share forecast
Total	29/40	No-trade screen; failed economics require Reject despite a Watchlist-range score

Bottom Line

FDA approval removes a major development risk for Atebrioz and gives Mirum a product expected to reach U.S. patients in October. Yet the company has not disclosed price, payer coverage, near-term sales expectations or evidence of patient uptake. Management’s greater-than-$200 million global peak estimate is not a launch-year forecast, while Incyte receives a $25 million approval milestone, continuing royalties and the voucher. At the $89.70 pre-announcement regular close, the price-only base is nearly flat and the downside stress is 24%. Reject / no trade.

AI Illustration Prompt

Create a sober editorial finance illustration for The Mispricing Desk: an FDA approval document for “ATEBRIOZ / zilurgisertib / FOP age 12+” on one side, and a commercial access pathway on the other with blank fields labeled “NET PRICE / PAYER COVERAGE / PATIENT STARTS / PERSISTENCE.” Below it, show “MIRM FY26 NET PRODUCT SALES GUIDE $680M–$700M,” “MANAGEMENT GLOBAL PEAK ESTIMATE >$200M FOR FULL BRAND / NOT LAUNCH-YEAR GUIDANCE,” and “INCYTE: $25M FDA APPROVAL MILESTONE + MID/HIGH-SINGLE-DIGIT ROYALTIES + PRV.” Include the 24-week trial facts “63 PATIENTS / −3.2 cm³ TREATMENT VS +24.6 cm³ PLACEBO” and price branches “TOP $109.50 / BASE $89.94 / BOTTOM $68.07,” stamped “REFERENCE ONLY / REJECT.” Clearly distinguish FDA-confirmed facts, issuer guidance, management peak estimate and analyst scenario assumptions. Use warm paper, graphite, soft teal and restrained amber; no generic candlesticks, invented logos or profit promises. Add a subtle readable “The Mispricing Desk” watermark in a wide 16:9 editorial composition.